Skye Bioscience rises as it partners with Halozyme on obesity drug

Skye Bioscience

05/01/2026 12:13

** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket

** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment

** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug

** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE

** Co plans mid-stage trial of new formulation in mid-2026

** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE

** As of last close, stock up ~17% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))